Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  ImmunoCellular Therapeutics Ltd    

 SummaryNewsCalendarCompanyFinancialsRevisions 
Financials ($)
More Financials
Company
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers.Its lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. 
More about the company
Latest news on IMMUNOCELLULAR THERAPEUTIC
06/28 JUNE 30 DEADLINE : Lundin Law PC Announces a Securities Class Action Lawsuit aga..
06/28 IMMUNOCELLULAR THERAPEUTICS LTD : UPCOMING DEADLINE: The Law Offices of Vincent ..
06/28 IMMUNOCELLULAR THERAPEUTICS LTD : DEADLINE ALERT: Bronstein, Gewirtz & Grossman,..
06/24 IMMUNOCELLULAR THERAPEUTICS LTD : ONE WEEK DEADLINE: Khang & Khang LLP Announces..
06/22 IMMUNOCELLULAR THERAPEUTICS, LTD. : Amendments to Articles of Inc. or Bylaws; Ch..
06/22 IMMUNOCELLULAR THERAPEUTICS LTD : DEADLINE APPROACHING: Lundin Law PC Announces ..
06/22 IMMUNOCELLULAR THERAPEUTICS LTD : Levi & Korsinsky, LLP Reminds ImmunoCellular T..
06/21 IMMUNOCELLULAR THERAPEUTICS, LTD. : Other Events, Financial Statements and Exhib..
06/21 IMMUNOCELLULAR THERAPEUTICS LTD : 9-DAY DEADLINE: Khang & Khang LLP Announces a ..
06/21 IMMUNOCELLULAR THERAPEUTICS LTD : Levi & Korsinsky, LLP Reminds ImmunoCellular T..
More news
Sector news : Biotechnology & Medical Research - NEC
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2016 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q3 2016 Results - Ea..
2016 ImmunoCellular Therapeutics EPS in-line
2016 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q2 2016 Results - Ea..
2016 ImmunoCellular Therapeutics beats by $0.01
2016 ImmunoCellular's late-stage study of lead product candidate in glioblastoma c..
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus
Number of Analysts
Average target price -
Spread / Average Target -100%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Anthony J. Gringeri President, Chief Executive Officer & Director
Gary S. Titus Chairman & Secretary
David E. Fractor Chief Financial Officer
John S. Yu Director
Rahul Singhvi Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOCELLULAR THERAPE..3
INCYTE CORPORATION29.96%26 684
QUINTILES IMS HOLDINGS..17.65%19 309
LONZA GROUP27.49%16 098
CELLTRION, INC.--.--%12 362
ALKERMES PLC4.89%8 750
More Results